RNA is far more than a passive messenger ferrying genetic instructions from DNA to the protein-making machinery of the cell. It folds into intricate three-dimensional shapes, catalyzes chemical reactions, regulates which genes get turned on or off, and even carries chemical tags that fine-tune its own behavior. That versatility has made RNA one of the most active frontiers in modern medicine, powering vaccines, gene-silencing drugs, and experimental editing tools that work directly on genetic messages without altering DNA itself.
How RNA Is Built and Why Its Shape Matters
At the chemical level, RNA and DNA are close relatives. Both are long chains of nucleotide building blocks, and both encode information in a four-letter alphabet. The differences are small but consequential. RNA uses the sugar ribose, which carries a hydroxyl group at a specific position on the ring, whereas DNA uses deoxyribose, which has a hydrogen atom in that same spot. RNA also swaps out one of DNA’s four bases, replacing thymine with uracil. These two tweaks, one on the sugar and one on the base, produce dramatically different behavior in three dimensions. DNA famously forms a stable double helix. RNA, by contrast, is primarily single-stranded and folds back on itself into complex shapes, with the hairpin being the most common secondary structure it adopts.1Journal of Chemical Theory and Computation. Ribose 2′-Hydroxyl Groups Stabilize RNA Hairpin Structures Containing GCUAA Pentaloop
That folding ability is the key to RNA’s versatility. A protein’s shape determines what it can do, and the same principle holds for RNA. A single-stranded messenger RNA can thread through the ribosome like a tape. A transfer RNA folds into a cloverleaf that grips an amino acid at one end and reads genetic code at the other. Ribosomal RNA, which makes up the core of the ribosome itself, folds into a structure so precise that it catalyzes the chemical reaction that links amino acids together during protein synthesis.2PubMed. The mechanism of peptidyl transfer catalysis by the ribosome The fact that RNA can both store information and perform chemistry is central to its importance in biology and to the growing number of medical tools built around it.
From Gene to Protein
The most familiar job of RNA is carrying genetic instructions out of the nucleus so they can be read by ribosomes. This process begins when an enzyme called RNA polymerase II copies a gene’s DNA sequence into a preliminary RNA transcript. That raw transcript is not yet ready for use. It undergoes three major processing steps: a chemical cap is added to the front end, internal non-coding stretches called introns are spliced out, and a tail of repeated adenine nucleotides is attached to the back end. All three of these reactions happen in close coordination with the polymerase as it moves along the DNA, rather than as separate afterthoughts.3PubMed Central. Capping, splicing, and 3′ processing are independently stimulated by RNA polymerase II: different functions for different segments of the CTD4Trends in Biochemical Sciences. Coupling transcription with pre-mRNA processing
Once the finished messenger RNA reaches the cytoplasm, it docks with a ribosome. The ribosome reads the message three nucleotides at a time, matching each triplet to a transfer RNA that delivers the corresponding amino acid. The ribosome then catalyzes the formation of a peptide bond, chaining amino acids together into a growing protein. When the ribosome hits a stop signal, it triggers a different chemical reaction, peptidyl hydrolysis, that frees the completed protein.2PubMed. The mechanism of peptidyl transfer catalysis by the ribosome This entire pipeline, from DNA to RNA to protein, is the central dogma of molecular biology. But RNA’s role doesn’t end there.
RNAs That Never Become Protein
A large and growing catalog of RNA molecules never get translated into protein at all. Instead, they regulate the activity of other genes. The best studied are microRNAs, small molecules roughly 21 nucleotides long. MicroRNAs work through a protein complex called RISC, which uses the microRNA as a guide to find and silence complementary messenger RNAs. Research has shown that processing the precursor hairpin form of a microRNA through the enzyme Dicer and directly into the RISC complex is roughly ten-fold more efficient at triggering target destruction than loading a pre-made mature microRNA.5Cell. Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing This coupling of microRNA production and silencing illustrates how tightly the cell integrates its regulatory machinery.
Long non-coding RNAs are another major class, defined loosely as non-coding transcripts longer than 200 nucleotides. They interact with proteins that modify chromatin, the structural packaging of DNA, and can influence whether whole regions of the genome are accessible for transcription. When their regulation goes awry, the downstream effects on gene expression can contribute to tumor development and progression.6PubMed Central. Alteration of Epigenetic Regulation by Long Noncoding RNAs in Cancer
Circular RNAs add yet another layer. Unlike typical linear RNAs, these molecules have their ends joined together, forming a closed loop that resists the enzymes that normally chew up RNA. Most are generated by an unusual splicing event in which the downstream end of an exon is joined back to the upstream end. Some circular RNAs act as “sponges,” soaking up microRNAs and preventing them from silencing their usual targets. Others sequester proteins, regulate transcription, and have been implicated in cancer biology.7PubMed Central. Emerging Functions of Circular RNAs
Chemical Tags on RNA
Just as DNA can be chemically modified to turn genes on or off, RNA carries its own suite of chemical decorations. The most abundant internal modification on messenger RNA is called m6A, a methyl group added to adenosine. This mark influences how quickly RNA is made, how efficiently it is translated, and how fast it is degraded. Disruptions in m6A patterns have been linked to cancer initiation, progression, and resistance to treatment.8PubMed Central. Role of N6-methyladenosine RNA modification in cancer
What makes this landscape especially intricate is that different modifications interact with one another. Research has revealed a previously underappreciated interplay between m6A and another common modification, A-to-I editing, in which an adenosine is chemically converted to inosine by ADAR enzymes. The two marks tend to be inversely correlated: when m6A levels drop on a transcript, that transcript binds more ADAR enzyme, and A-to-I editing goes up.9PubMed. N(6)-Methyladenosines Modulate A-to-I RNA Editing A-to-I editing and m6A can even occupy the same adenosine position on an RNA molecule, though traditional methods studied each modification independently. Newer techniques allow researchers to detect both modifications simultaneously at the same site.10PubMed. Simultaneous Detection of Adenosine-to-Inosine Editing and N(6)-Methyladenosine at Identical RNA Sites through Deamination-Assisted Reverse Transcription Stalling This field, sometimes called epitranscriptomics, is still young, but it is already clear that the chemical landscape on RNA is far richer and more dynamic than anyone suspected a few decades ago.
Quality Control and RNA Localization
Cells do not blindly translate every RNA that reaches the cytoplasm. A surveillance system called nonsense-mediated mRNA decay, or NMD, monitors messenger RNAs during translation. If a ribosome encounters a premature stop signal, which can arise from mutations or errors in splicing, a set of conserved proteins called the Upf factors tag that transcript for rapid destruction. This prevents the cell from producing truncated proteins that could be toxic or non-functional.11PubMed Central. Nonsense-Mediated mRNA Decay: Degradation of Defective Transcripts Is Only Part of the Story NMD is not limited to cleaning up mistakes; it also regulates the levels of many normal transcripts, shaping gene expression in ways that go beyond simple error correction.
Location matters, too. Neurons are an extreme example: their axons and dendrites can extend long distances from the cell body, and ferrying every needed protein all the way from the nucleus would be inefficient. Instead, neurons ship certain messenger RNAs to specific compartments in a translationally silent state, then activate translation locally when and where a particular protein is needed. Live imaging of fluorescently tagged molecules has revealed conserved mechanisms that guide RNAs into the correct cellular compartments.12PubMed Central. mRNA localization and local translation in neurons This local translation strategy is essential for processes like memory formation and axon guidance, where rapid, spatially precise protein production matters.
Stress Granules and Phase Separation
When a cell encounters stress, such as heat, oxidative damage, or viral infection, it can rapidly shut down most of its translation machinery and sweep untranslated mRNAs into dense, membrane-less clusters called stress granules. These structures form through a physical process known as liquid-liquid phase separation, in which RNA and RNA-binding proteins condense into droplet-like compartments the way oil separates from water.13PubMed Central. Biomolecular phase separation in stress granule assembly and virus infection
Stress granules are meant to be temporary. Once the stress passes, they dissolve and translation resumes. But if the proteins driving their assembly carry mutations, particularly in their low-complexity domains, the liquid droplets can solidify into pathological fibrils. Research has connected this transition from liquid to solid with neurodegenerative diseases, suggesting that persistent stress granules may seed the protein aggregates seen in conditions like amyotrophic lateral sclerosis.14PubMed Central. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization RNA is not a bystander in this process; it directly participates in phase separation, and changes in the RNA composition of these granules may determine whether they remain benign or become harmful.
RNA as a Diagnostic Tool
Because RNA reflects which genes are actively being expressed at a given moment, fragments of it that leak out of cells and into body fluids carry real-time information about what is happening inside tissues. These cell-free RNAs, found in blood, urine, saliva, and cerebrospinal fluid, are emerging as biomarkers for a growing range of diseases. Non-coding RNAs, including microRNAs and long non-coding RNAs, are especially attractive because of their stability and their regulatory roles in development and disease. Researchers are exploring them as markers for diagnosis, prognosis, and treatment monitoring in conditions ranging from autoimmune diseases to cancer.15PubMed Central. Proceedings of cell-free noncoding RNA biomarker studies in liquid biopsy
Cardiovascular disease is a promising application area. Obtaining tissue samples from atherosclerotic plaques or from deep vein clots is invasive and often impractical. Cell-free RNA profiling from a blood draw offers a non-invasive alternative that can capture dynamic molecular information about the disease state. Combined with established cardiovascular biomarkers, cell-free RNA analysis may help with early detection and ongoing monitoring of conditions that are otherwise difficult to track.16PubMed. Nucleic acid liquid biopsies in cardiovascular disease: Cell-free RNA liquid biopsies in cardiovascular disease
RNA-Based Therapeutics
The idea of using RNA itself as a drug has moved from speculation to approved treatments within the last decade, though the specific strategies vary widely.
Antisense oligonucleotides, or ASOs, are short synthetic stretches of modified nucleotides designed to bind a specific pre-mRNA. One class, called splice-switching oligonucleotides, works by blocking the interactions between the cell’s splicing machinery and the pre-mRNA, forcing a change in how introns and exons are assembled. Their nucleotides are chemically modified so that the cell’s RNA-cleaving enzymes do not destroy the target transcript. The goal is to alter splicing, not to reduce the amount of mRNA, which makes them useful for diseases caused by splicing errors.17PubMed Central. Splice-switching antisense oligonucleotides as therapeutic drugs Approved drugs in this category treat conditions like spinal muscular atrophy and Duchenne muscular dystrophy.
Small interfering RNAs take a different approach. These short double-stranded molecules harness the cell’s own RISC machinery, the same system microRNAs use, to silence a specific gene. The challenge is delivering them to the right tissue. One strategy uses a sugar molecule called GalNAc to target the siRNA to liver cells, which carry a receptor that specifically recognizes it. Lipid nanoparticles carrying GalNAc-modified siRNA can achieve targeted gene silencing with good stability and biocompatibility.18Materials Today Bio. Dual targeted gene delivery strategy mediated by GalNAc-modified lipid nanoparticles enhances liver regeneration through specific knockdown of MKK4 Several siRNA drugs are now approved for liver-related conditions, including hereditary transthyretin amyloidosis.
mRNA Vaccines and the Nucleoside Modification Breakthrough
The COVID-19 pandemic brought mRNA vaccines into the spotlight, but the science behind them had been building for years. A key breakthrough was discovering that replacing uridine in synthetic mRNA with a modified nucleoside, N1-methylpseudouridine, dramatically reduces the innate immune system’s hostile reaction to the foreign RNA.19Nature Reviews Materials. Lipid nanoparticles for mRNA delivery Without that modification, the body’s pattern-recognition systems treat injected mRNA as a viral invader and trigger inflammatory pathways that suppress translation, meaning less protein gets made from the vaccine.
How much difference does the modification make? In primate studies, mRNA carrying N1-methylpseudouridine delivered in lipid nanoparticles produced antibody titers roughly a hundred-fold higher than unmodified mRNA in the same type of nanoparticle.20PubMed Central. The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system The effect varies depending on the lipid nanoparticle formulation used; some nanoparticles already produce strong responses with unmodified mRNA and see a modest boost from the modification, while others benefit enormously. RNA sequencing data from primate studies has confirmed that unmodified mRNA triggers stronger activation of interferon-related immune pathways, which in turn suppresses translation. Modified mRNA dials down that alarm, allowing the cell to produce more of the target protein.21npj Vaccines. Synergistic effect of nucleoside modification and ionizable lipid composition on translation and immune responses to mRNA vaccines
RNA-Targeting Gene Editing
CRISPR is best known for cutting DNA, but a related family of enzymes called Cas13 targets RNA instead. This is an appealing distinction: editing RNA leaves the genome untouched, and any changes are temporary because RNA molecules are naturally degraded over time. Initial work showed that a version called LwaCas13a could knock down specific transcripts in mammalian cells with efficiency comparable to traditional RNA interference, and with improved specificity.22Nature. RNA targeting with CRISPR–Cas13 More recent structural studies are illuminating exactly where different Cas13 subtypes cut their target RNA, and rational engineering is improving precision further.23Nature Communications. Molecular basis of target RNA cleavage by Cas13
A related strategy sidesteps cutting altogether and instead chemically edits individual bases on an RNA molecule. The cell’s own ADAR enzymes naturally convert adenosine to inosine, and researchers have designed guide RNAs that recruit ADAR to a chosen site. Early versions of this approach suffered from low efficiency, but newer designs, including circular guide RNAs and computationally optimized “CLUSTER” guides that grip the target in multiple places, are achieving much higher editing rates both in cell culture and in living animals.24PubMed Central. Programmable RNA editing with endogenous ADAR enzymes – a feasible option for the treatment of inherited retinal disease?25Nature Biotechnology. CLUSTER guide RNAs enable precise and efficient RNA editing with endogenous ADAR enzymes in vivo Because this approach recruits the body’s own editing enzyme rather than introducing a foreign protein, it avoids some of the immune concerns that come with other gene-therapy strategies. Inherited retinal diseases, where a small, accessible tissue needs correction, are an early testing ground.
The Delivery Problem
For all the promise of RNA-based therapies, getting the molecules to the right cells remains the field’s biggest practical hurdle. Naked RNA is quickly chewed up by enzymes in the blood and cannot easily cross cell membranes. Even encapsulated in lipid nanoparticles, most RNA drugs currently approved target the liver, because the liver naturally takes up these particles. Expanding RNA therapy to the brain, lungs, joints, or tumors requires solving a separate delivery puzzle for each tissue. Multiple physiological barriers compromise the therapeutic efficacy of RNA drugs in the body, and this limitation has led to the termination of many clinical trials.26PubMed Central. RNA Therapeutics: Delivery Problems and Solutions-A Review27PubMed. Overcoming delivery barriers for RNA therapeutics in the treatment of rheumatoid arthritis
The result is a curious asymmetry in the field. The list of diseases where researchers have identified a promising RNA target is long and growing. The list of diseases where an RNA drug has actually been approved is still short and skewed toward rare conditions and liver-centric targets. Closing that gap depends on advances in targeted delivery systems, better chemical modifications that extend RNA stability, and a more granular understanding of how different tissues take up and process nanoparticles.26PubMed Central. RNA Therapeutics: Delivery Problems and Solutions-A Review
How Viruses Exploit and Trigger the RNA System
Many of the viruses that infect humans, including influenza, SARS-CoV-2, Ebola, and hepatitis C, carry RNA genomes. When these viruses enter a cell, they hijack the host’s RNA machinery to replicate their own genetic material and make viral proteins. The cell is not defenseless: pattern recognition receptors in the innate immune system detect foreign RNA structures and activate signaling pathways that produce interferons and pro-inflammatory cytokines, rallying an antiviral response and priming the adaptive immune system.28PubMed Central. Innate immune responses in RNA viral infection
This same detection system is what makes unmodified synthetic mRNA so inflammatory when injected as a vaccine, which is why the nucleoside modification discussed earlier matters so much. The interplay between viral RNA and human immune sensing is also relevant to understanding why some RNA viruses cause mild illness while others provoke severe immune overreaction. Differences in the RNA structures viruses produce, and in how effectively they evade the host’s sensors, help explain the wide range of disease severity across RNA virus families.
RNA and the Origin of Life
The versatility of RNA raises a profound evolutionary question. In modern cells, DNA stores genetic information and proteins carry out chemical work. But RNA can do both. It stores genetic information in RNA viruses, and it catalyzes one of biology’s most fundamental reactions, peptide bond formation, at the heart of the ribosome. This dual ability is the foundation of the RNA world hypothesis, which proposes that early life was based on RNA molecules that both replicated themselves and catalyzed necessary chemistry, before DNA and proteins took over their separate modern roles.29BioDirect. The RNA world hypothesis: the worst theory of the early evolution of life (except for all the others)
From a biosynthetic standpoint, DNA is essentially a modified RNA, which makes the case that RNA came first at least chemically plausible. The hypothesis remains debated and has well-known weaknesses, particularly around how the first RNA molecules could have assembled without the help of enzymes. But among the available proposals for how life got started, it has the widest support and the fewest fatal objections. The title of one influential review captures the consensus well: it called the RNA world “the worst theory of the early evolution of life, except for all the others.”29BioDirect. The RNA world hypothesis: the worst theory of the early evolution of life (except for all the others)